Skip to main content

Anticoagulation

2
Pipeline Programs
5
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
ApixabanPhase 41 trial
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyN/A
Active Trials
NCT01884337Completed557Est. Jun 2018
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
four factor prothrombin complex concentratePhase 4
Bristol Myers Squibb
1 program
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyN/A1 trial
Active Trials
NCT02921126Completed9,914Est. Aug 2018
CSL Behring
CSL BehringIL - Bradley
1 program
four factor prothrombin complex concentratePHASE_41 trial
Active Trials
NCT03473132Unknown50Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL Behringfour factor prothrombin complex concentrate
PfizerApixaban
Bristol Myers SquibbReal-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Clinical Trials (3)

Total enrollment: 10,521 patients across 3 trials

NCT03473132CSL Behringfour factor prothrombin complex concentrate

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

Start: Mar 2018Est. completion: Mar 202250 patients
Phase 4Unknown
NCT01884337PfizerApixaban

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Start: Mar 2015Est. completion: Jun 2018557 patients
Phase 4Completed
NCT02921126Bristol Myers SquibbReal-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Start: Apr 2017Est. completion: Aug 20189,914 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.